|
2025-02-18 |
2025-02-14 |
S
Sale
|
Herr Amy E.
Non-Executive Director
|
1,860
-48.5%
65.96
USD 122,691
|
1,860
-48.5%
|
65.96
|
USD 122,691
|
|
|
2025-01-29 |
2025-01-27 |
S
Sale
|
Kelderman Kim
Chief Executive Officer
Executive Director
|
1,661
-4.1%
77.95
USD 129,480
|
1,661
-4.1%
|
77.95
|
USD 129,480
|
|
|
2025-01-29 |
2025-01-27 |
S
Sale
|
Kelderman Kim
Chief Executive Officer
Executive Director
|
11,731
-22.4%
77.19
USD 905,533
|
11,731
-22.4%
|
77.19
|
USD 905,533
|
|
|
2024-08-12 |
2024-08-08 |
S
Sale
|
BAUMGARTNER ROBERT V
Non-Executive Director
|
16,000
-26.9%
72.10
USD 1,153,664
|
16,000
-26.9%
|
72.10
|
USD 1,153,664
|
|
|
2024-05-16 |
2024-05-14 |
S
Sale
|
HIGGINS JOHN L
Non-Executive Director
|
4,000
-9.9%
83.84
USD 335,377
|
4,000
-9.9%
|
83.84
|
USD 335,377
|
|
|
2024-03-11 |
2024-03-07 |
S
Sale
|
Nusse Roeland
Non-Executive Director
|
10,400
-19.4%
76.98
USD 800,627
|
10,400
-19.4%
|
76.98
|
USD 800,627
|
|
|
2023-09-01 |
2023-08-30 |
S
Sale
|
Nusse Roeland
Non-Executive Director
|
8,939
-14.7%
80.32
USD 717,959
|
8,939
-14.7%
|
80.32
|
USD 717,959
|
|
|
2023-07-25 |
2023-07-21 |
PS
Planned sale
|
Kummeth Charles R.
Chief Executive Officer
Executive Director
|
80,000
-6.0%
88.36
USD 7,069,024
|
80,000
-6.0%
|
88.36
|
USD 7,069,024
|
|
|
2023-06-09 |
2023-06-07 |
S
Sale
|
Kummeth Charles R.
Chief Executive Officer
Executive Director
|
322
-0.0%
83.00
USD 26,726
|
322
-0.0%
|
83.00
|
USD 26,726
|
|
|
2022-12-09 |
2022-12-08 |
S
Sale
|
Furlow Brenda S.
SVP - GENERAL COUNSEL
Officer
|
7,450
-22.2%
82.12
USD 611,810
|
7,450
-22.2%
|
82.12
|
USD 611,810
|
|
|
2022-12-09 |
2022-12-07 |
S
Sale
|
Furlow Brenda S.
SVP - GENERAL COUNSEL
Officer
|
800
-3.0%
82.01
USD 65,605
|
800
-3.0%
|
82.01
|
USD 65,605
|
|
|
2022-08-12 |
2022-08-11 |
S
Sale
|
HIGGINS JOHN L
Non-Executive Director
|
8
-0.1%
380.71
USD 3,046
|
8
-0.1%
|
380.71
|
USD 3,046
|
|
|
2022-08-12 |
2022-08-11 |
S
Sale
|
HIGGINS JOHN L
Non-Executive Director
|
504
-8.4%
385.47
USD 194,277
|
504
-8.4%
|
385.47
|
USD 194,277
|
|
|
2022-08-12 |
2022-08-10 |
S
Sale
|
HIGGINS JOHN L
Non-Executive Director
|
992
-14.2%
380.15
USD 377,112
|
992
-14.2%
|
380.15
|
USD 377,112
|
|
|
2022-08-12 |
2022-08-10 |
S
Sale
|
HIGGINS JOHN L
Non-Executive Director
|
100
-1.4%
374.90
USD 37,490
|
100
-1.4%
|
374.90
|
USD 37,490
|
|
|
2022-08-12 |
2022-08-10 |
S
Sale
|
HIGGINS JOHN L
Non-Executive Director
|
900
-11.2%
373.99
USD 336,593
|
900
-11.2%
|
373.99
|
USD 336,593
|
|
|
2022-06-09 |
2022-06-08 |
S
Sale
|
HIGGINS JOHN L
Non-Executive Director
|
600
-11.5%
366.09
USD 219,654
|
600
-11.5%
|
366.09
|
USD 219,654
|
|
|
2022-06-09 |
2022-06-07 |
S
Sale
|
Kummeth Charles R.
CHIEF EXECUTIVE OFFICER
Executive Director
|
5,104
-2.5%
365.00
USD 1,862,960
|
5,104
-2.5%
|
365.00
|
USD 1,862,960
|
|
|
2022-06-09 |
2022-06-07 |
S
Sale
|
HIGGINS JOHN L
Non-Executive Director
|
1,000
-17.8%
364.31
USD 364,310
|
1,000
-17.8%
|
364.31
|
USD 364,310
|
|
|
2022-05-11 |
2022-05-10 |
B
Purchase
|
BAUMGARTNER ROBERT V
Non-Executive Director
|
300
+3.1%
352.55
USD 105,765
|
300
+3.1%
|
352.55
|
USD 105,765
|
|
|
2021-11-23 |
2021-11-19 |
S
Sale
|
Kelderman Kim
Pres. Diagnostics & Genom
Officer
|
400
-100.0%
505.78
USD 202,313
|
400
-100.0%
|
505.78
|
USD 202,313
|
|
|
2021-11-23 |
2021-11-19 |
S
Sale
|
Kelderman Kim
Pres. Diagnostics & Genom
Officer
|
100
-20.0%
503.76
USD 50,376
|
100
-20.0%
|
503.76
|
USD 50,376
|
|
|
2021-11-16 |
2021-11-12 |
S
Sale
|
Eansor Norman David
President-Protein Sciences
Officer
|
401
-23.3%
506.24
USD 203,002
|
401
-23.3%
|
506.24
|
USD 203,002
|
|
|
2021-11-16 |
2021-11-12 |
S
Sale
|
Eansor Norman David
President-Protein Sciences
Officer
|
2,535
-59.6%
505.49
USD 1,281,407
|
2,535
-59.6%
|
505.49
|
USD 1,281,407
|
|
|
2021-11-16 |
2021-11-12 |
S
Sale
|
Eansor Norman David
President-Protein Sciences
Officer
|
8,989
-67.9%
504.39
USD 4,533,985
|
8,989
-67.9%
|
504.39
|
USD 4,533,985
|
|
|
2021-11-16 |
2021-11-12 |
S
Sale
|
Eansor Norman David
President-Protein Sciences
Officer
|
9,043
-40.6%
503.61
USD 4,554,137
|
9,043
-40.6%
|
503.61
|
USD 4,554,137
|
|
|
2021-11-16 |
2021-11-12 |
S
Sale
|
Eansor Norman David
President-Protein Sciences
Officer
|
4,054
-15.4%
502.77
USD 2,038,221
|
4,054
-15.4%
|
502.77
|
USD 2,038,221
|
|
|
2021-11-16 |
2021-11-12 |
S
Sale
|
Eansor Norman David
President-Protein Sciences
Officer
|
400
-1.5%
505.01
USD 202,002
|
400
-1.5%
|
505.01
|
USD 202,002
|
|
|
2021-11-16 |
2021-11-12 |
S
Sale
|
Eansor Norman David
President-Protein Sciences
Officer
|
537
-2.0%
504.14
USD 270,725
|
537
-2.0%
|
504.14
|
USD 270,725
|
|
|
2021-11-16 |
2021-11-12 |
S
Sale
|
Eansor Norman David
President-Protein Sciences
Officer
|
300
-1.1%
502.99
USD 150,897
|
300
-1.1%
|
502.99
|
USD 150,897
|
|
|
2021-11-16 |
2021-11-12 |
S
Sale
|
Eansor Norman David
President-Protein Sciences
Officer
|
200
-0.7%
504.78
USD 100,956
|
200
-0.7%
|
504.78
|
USD 100,956
|
|
|
2021-11-16 |
2021-11-12 |
S
Sale
|
Eansor Norman David
President-Protein Sciences
Officer
|
700
-2.5%
504.09
USD 352,860
|
700
-2.5%
|
504.09
|
USD 352,860
|
|
|
2021-11-03 |
2021-11-02 |
PS
Planned sale
|
Hippel James
Chief Financial Officer
Officer
|
200
-1.8%
525.10
USD 105,020
|
200
-1.8%
|
525.10
|
USD 105,020
|
|
|
2021-11-03 |
2021-11-01 |
PS
Planned sale
|
Hippel James
Chief Financial Officer
Officer
|
943
-8.1%
528.55
USD 498,427
|
943
-8.1%
|
528.55
|
USD 498,427
|
|
|
2021-11-03 |
2021-11-01 |
PS
Planned sale
|
Hippel James
Chief Financial Officer
Officer
|
1,433
-10.9%
527.50
USD 755,903
|
1,433
-10.9%
|
527.50
|
USD 755,903
|
|
|
2021-11-03 |
2021-11-01 |
PS
Planned sale
|
Hippel James
Chief Financial Officer
Officer
|
2,880
-18.0%
526.50
USD 1,516,321
|
2,880
-18.0%
|
526.50
|
USD 1,516,321
|
|
|
2021-11-03 |
2021-11-01 |
PS
Planned sale
|
Hippel James
Chief Financial Officer
Officer
|
3,566
-18.2%
525.61
USD 1,874,318
|
3,566
-18.2%
|
525.61
|
USD 1,874,318
|
|
|
2021-11-01 |
2021-10-29 |
PS
Planned sale
|
Hippel James
Chief Financial Officer
Officer
|
662
-5.8%
525.23
USD 347,704
|
662
-5.8%
|
525.23
|
USD 347,704
|
|
|
2021-11-01 |
2021-10-28 |
PS
Planned sale
|
Hippel James
Chief Financial Officer
Officer
|
100
-0.9%
525.18
USD 52,518
|
100
-0.9%
|
525.18
|
USD 52,518
|
|
|
2021-09-02 |
2021-08-31 |
S
Sale
|
Eansor Norman David
President-Protein Sciences
Officer
|
1,538
-53.9%
503.07
USD 773,728
|
1,538
-53.9%
|
503.07
|
USD 773,728
|
|
|
2021-09-02 |
2021-08-31 |
S
Sale
|
Furlow Brenda S.
SVP - General Counsel
Officer
|
3,108
-29.0%
506.12
USD 1,573,011
|
3,108
-29.0%
|
506.12
|
USD 1,573,011
|
|
|
2021-09-02 |
2021-08-31 |
S
Sale
|
Furlow Brenda S.
SVP - General Counsel
Officer
|
1,569
-12.8%
505.26
USD 792,755
|
1,569
-12.8%
|
505.26
|
USD 792,755
|
|
|
2021-09-02 |
2021-08-31 |
S
Sale
|
Furlow Brenda S.
SVP - General Counsel
Officer
|
323
-2.6%
503.24
USD 162,546
|
323
-2.6%
|
503.24
|
USD 162,546
|
|
|
2021-08-10 |
2021-08-09 |
S
Sale
|
Hippel James
Chief Financial Officer
Officer
|
300
-2.7%
484.98
USD 145,494
|
300
-2.7%
|
484.98
|
USD 145,494
|
|
|
2021-08-10 |
2021-08-09 |
S
Sale
|
Hippel James
Chief Financial Officer
Officer
|
300
-2.6%
483.62
USD 145,085
|
300
-2.6%
|
483.62
|
USD 145,085
|
|
|
2021-08-10 |
2021-08-09 |
S
Sale
|
Hippel James
Chief Financial Officer
Officer
|
300
-2.6%
481.61
USD 144,482
|
300
-2.6%
|
481.61
|
USD 144,482
|
|
|
2021-08-10 |
2021-08-09 |
S
Sale
|
Hippel James
Chief Financial Officer
Officer
|
700
-5.6%
480.66
USD 336,462
|
700
-5.6%
|
480.66
|
USD 336,462
|
|
|
2021-08-10 |
2021-08-09 |
S
Sale
|
Hippel James
Chief Financial Officer
Officer
|
100
-0.8%
480.70
USD 48,070
|
100
-0.8%
|
480.70
|
USD 48,070
|
|
|
2021-08-10 |
2021-08-09 |
S
Sale
|
Hippel James
Chief Financial Officer
Officer
|
1,300
-9.4%
479.96
USD 623,954
|
1,300
-9.4%
|
479.96
|
USD 623,954
|
|
|
2021-08-10 |
2021-08-09 |
S
Sale
|
Hippel James
Chief Financial Officer
Officer
|
1,800
-11.5%
478.58
USD 861,444
|
1,800
-11.5%
|
478.58
|
USD 861,444
|
|
|
2021-08-10 |
2021-08-09 |
S
Sale
|
Hippel James
Chief Financial Officer
Officer
|
5,200
-24.9%
477.69
USD 2,484,002
|
5,200
-24.9%
|
477.69
|
USD 2,484,002
|
|
|
2021-06-21 |
2021-06-18 |
PS
Planned sale
|
Kummeth Charles R.
Chief Executive Officer
Executive Director
|
326
-0.2%
450.37
USD 146,821
|
326
-0.2%
|
450.37
|
USD 146,821
|
|
|
2021-06-21 |
2021-06-18 |
PS
Planned sale
|
Kummeth Charles R.
Chief Executive Officer
Executive Director
|
2,583
-1.6%
449.09
USD 1,159,999
|
2,583
-1.6%
|
449.09
|
USD 1,159,999
|
|
|
2021-06-21 |
2021-06-17 |
PS
Planned sale
|
Kummeth Charles R.
Chief Executive Officer
Executive Director
|
109
-0.1%
452.13
USD 49,282
|
109
-0.1%
|
452.13
|
USD 49,282
|
|
|
2021-06-21 |
2021-06-17 |
PS
Planned sale
|
Kummeth Charles R.
Chief Executive Officer
Executive Director
|
1,050
-0.7%
451.54
USD 474,117
|
1,050
-0.7%
|
451.54
|
USD 474,117
|
|
|
2021-06-21 |
2021-06-17 |
PS
Planned sale
|
Kummeth Charles R.
Chief Executive Officer
Executive Director
|
1,698
-1.1%
450.39
USD 764,762
|
1,698
-1.1%
|
450.39
|
USD 764,762
|
|
|
2021-06-21 |
2021-06-17 |
PS
Planned sale
|
Kummeth Charles R.
Chief Executive Officer
Executive Director
|
6,732
-4.0%
449.35
USD 3,025,024
|
6,732
-4.0%
|
449.35
|
USD 3,025,024
|
|
|
2021-06-16 |
2021-06-14 |
PS
Planned sale
|
Kummeth Charles R.
Chief Executive Officer
Executive Director
|
349
-0.2%
450.10
USD 157,085
|
349
-0.2%
|
450.10
|
USD 157,085
|
|
|
2021-06-16 |
2021-06-14 |
PS
Planned sale
|
Kummeth Charles R.
Chief Executive Officer
Executive Director
|
7,132
-4.1%
449.10
USD 3,202,981
|
7,132
-4.1%
|
449.10
|
USD 3,202,981
|
|
|
2021-02-17 |
2021-02-12 |
S
Sale
|
Furlow Brenda S.
SVP - General Counsel
Officer
|
3,326
-35.2%
399.12
USD 1,327,461
|
3,326
-35.2%
|
399.12
|
USD 1,327,461
|
|
|
2021-02-17 |
2021-02-12 |
S
Sale
|
Furlow Brenda S.
SVP - General Counsel
Officer
|
6,674
-41.4%
398.40
USD 2,658,891
|
6,674
-41.4%
|
398.40
|
USD 2,658,891
|
|
|
2021-02-17 |
2021-02-12 |
S
Sale
|
Hippel James
Chief Financial Officer
Officer
|
600
-6.2%
401.52
USD 240,911
|
600
-6.2%
|
401.52
|
USD 240,911
|
|
|
2021-02-17 |
2021-02-12 |
S
Sale
|
Hippel James
Chief Financial Officer
Officer
|
9,400
-49.1%
400.32
USD 3,762,998
|
9,400
-49.1%
|
400.32
|
USD 3,762,998
|
|
|
2021-02-10 |
2021-02-08 |
S
Sale
|
Nusse Roeland
Non-Executive Director
|
6,000
-47.0%
385.08
USD 2,310,481
|
6,000
-47.0%
|
385.08
|
USD 2,310,481
|
|
|
2021-02-09 |
2021-02-05 |
S
Sale
|
Eansor Norman David
President-Protein Sciences
Officer
|
1,100
-45.5%
385.59
USD 424,151
|
1,100
-45.5%
|
385.59
|
USD 424,151
|
|
|
2021-02-09 |
2021-02-05 |
S
Sale
|
Eansor Norman David
President-Protein Sciences
Officer
|
1,900
-44.0%
384.15
USD 729,888
|
1,900
-44.0%
|
384.15
|
USD 729,888
|
|
|
2021-02-09 |
2021-02-05 |
S
Sale
|
Eansor Norman David
President-Protein Sciences
Officer
|
3,700
-46.1%
382.60
USD 1,415,636
|
3,700
-46.1%
|
382.60
|
USD 1,415,636
|
|
|
2021-02-09 |
2021-02-05 |
S
Sale
|
Eansor Norman David
President-Protein Sciences
Officer
|
2,900
-26.6%
381.52
USD 1,106,395
|
2,900
-26.6%
|
381.52
|
USD 1,106,395
|
|
|
2021-02-09 |
2021-02-05 |
S
Sale
|
Eansor Norman David
President-Protein Sciences
Officer
|
12,833
-54.0%
380.50
USD 4,882,918
|
12,833
-54.0%
|
380.50
|
USD 4,882,918
|
|
|
2021-02-09 |
2021-02-05 |
S
Sale
|
Eansor Norman David
President-Protein Sciences
Officer
|
4,500
-15.9%
379.62
USD 1,708,312
|
4,500
-15.9%
|
379.62
|
USD 1,708,312
|
|
|
2021-02-09 |
2021-02-05 |
S
Sale
|
Eansor Norman David
President-Protein Sciences
Officer
|
6,000
-17.5%
378.29
USD 2,269,723
|
6,000
-17.5%
|
378.29
|
USD 2,269,723
|
|
|
2021-02-09 |
2021-02-05 |
S
Sale
|
Kelderman Kim
Pres. Diagnostics & Genom
Officer
|
823
-49.3%
388.45
USD 319,694
|
823
-49.3%
|
388.45
|
USD 319,694
|
|
|
2021-01-20 |
2021-01-15 |
PS
Planned sale
|
Kummeth Charles R.
Chief Executive Officer
Executive Director
|
20,000
-12.0%
344.00
USD 6,880,000
|
20,000
-12.0%
|
344.00
|
USD 6,880,000
|
|
|
2021-01-13 |
2021-01-11 |
PS
Planned sale
|
Hippel James
Chief Financial Officer
Officer
|
2,009
-18.0%
334.98
USD 672,983
|
2,009
-18.0%
|
334.98
|
USD 672,983
|
|
|
2021-01-13 |
2021-01-11 |
PS
Planned sale
|
Hippel James
Chief Financial Officer
Officer
|
3,990
-26.4%
334.39
USD 1,334,219
|
3,990
-26.4%
|
334.39
|
USD 1,334,219
|
|
